Drug pricing regulator National Pharmaceutical Pricing Authority (NPPA) has revises ceiling prices of 18 scheduled formulations of Schedule-I under Drugs (Price Control) Amendment Order, 2016 under DPCO, 2013 as per notification/order dated 10 March 2017.  

Griseofulvin tablet, methyldopa tablet, human normal immunoglobulin, vitamin A tablet, calamine lotion, amphotericin B powder for injection - conventional, amphotericin B powder for injection - lipid/liposomal, acetylsalicylic acid tablet, verapamil injection, verapamil tablet, methyldopa tablet, vitamin A injection, furosemide tablet, furosemide injection, bupivacaine injection, lignocaine topical forms and verapamil tablet.

The concerned manufacturers of these formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and/or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

In case the retail price of any of the formulations is not complied with, as per instant price notification and notes specified, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

Consequent to the issue of retail price of the formulations as specified in this notification, the price order(s) if any, issued for concerned manufacturer/marketeer prior to said date of notification, stand(s) superseded.